SCHEMBL15944982

SCHEMBL15944982

O=C(Nc1nc2c(Cl)cc(Cl)cc2[nH]1)C1CC1c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LPAR2 Q9HBW0 4/20 0.72
LMNA P02545 2/20 0.46
NAMPT P43490 1/20 0.46
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TRPM5 Q9NZQ8 1/20 0.45
DEGS1 O15121 1/20 0.44
HDAC4 P56524 1/20 0.44
MAOB P27338 1/20 0.44
ADORA2A P29274 1/20 0.44
ADORA2B P29275 1/20 0.44
ADORA1 P30542 1/20 0.44
SLC6A9 P48067 1/20 0.44
CFD P00746 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15944951 0.83 LPAR2 (1.00) LPAR2LMNANAMPTALDH1A1GAA
SCHEMBL15944964 0.82 LPAR2 (0.78) LPAR2LMNANAMPTALDH1A1GAA
SCHEMBL15944985 0.81 LPAR2 (0.84) LPAR2LMNANAMPTALDH1A1GAA
SCHEMBL15944997 0.78 LPAR2 (0.72) LPAR2LMNANAMPTALDH1A1GAA
SCHEMBL15938994 0.78 LPAR2 (0.77) LPAR2LMNANAMPTALDH1A1GAA
SCHEMBL15944991 0.78 LPAR2 (0.59) LPAR2LMNANAMPTALDH1A1GAA
SCHEMBL15944949 0.76 LPAR2 (0.76) LPAR2LMNASMN1; SMN2
SCHEMBL15944961 0.76 LPAR2 (0.77) LPAR2SMN1; SMN2TRPM5
SCHEMBL15944968 0.76 LPAR2 (0.71) LPAR2LMNANAMPTALDH1A1GAA
SCHEMBL15939272 0.76 LPAR2 (0.68) LPAR2LMNANAMPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8912202-B2 N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists MERCK PATENT GMBH (DE) 2014-12-16 US disclosed
US-8912202-B2 N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists MERCK PATENT GMBH (DE) 2014-12-16 US disclosed
US-20140228378-A1 N-(Benzimimdazol-2-yl)-Cyclopropane Carboxamides as Lysophosphatidic Acid Antagonists MERCK PATENT GMBH (DE) 2014-08-14 US disclosed
US-20140228378-A1 N-(Benzimimdazol-2-yl)-Cyclopropane Carboxamides as Lysophosphatidic Acid Antagonists MERCK PATENT GMBH (DE) 2014-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140228378-A1 N-(Benzimimdazol-2-yl)-Cyclopropane Carboxamides as Lysophosphatidic Acid Antagonists LPAR5, LPAR2, LPAR1 LPAR2 2/4885LMNA 1255/4885NAMPT 1018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.